222 related articles for article (PubMed ID: 35142153)
21. Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Song J; Ma Q; Gao W; Cong Z; Xie J; Zimmerman Z; Belton L; Franklin J; Palmer S
Adv Ther; 2019 Apr; 36(4):950-961. PubMed ID: 30758745
[TBL] [Abstract][Full Text] [Related]
22. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.
George B; Kantarjian H; Jabbour E; Jain N
Immunotherapy; 2016 Feb; 8(2):135-43. PubMed ID: 26780449
[TBL] [Abstract][Full Text] [Related]
23. A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation.
Izumi A; Tachibana T; Ando T; Tanaka M; Kanamori H; Nakajima H
Int J Hematol; 2022 Jan; 115(1):69-76. PubMed ID: 34490598
[TBL] [Abstract][Full Text] [Related]
24. Clinical Significance of Inotuzumab Ozogamicin in Non-transplant Patients with Relapsed Acute Lymphoblastic Leukemia: A Report of Four Cases.
Okura M; Ida N; Yamauchi T
Intern Med; 2020 Aug; 59(16):2047-2051. PubMed ID: 32389945
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
Stock W; Martinelli G; Stelljes M; DeAngelo DJ; Gökbuget N; Advani AS; O'Brien S; Liedtke M; Merchant AA; Cassaday RD; Wang T; Zhang H; Vandendries E; Jabbour E; Marks DI; Kantarjian HM
Cancer; 2021 Mar; 127(6):905-913. PubMed ID: 33231879
[TBL] [Abstract][Full Text] [Related]
26. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.
Kantarjian H; Thomas D; Jorgensen J; Kebriaei P; Jabbour E; Rytting M; York S; Ravandi F; Garris R; Kwari M; Faderl S; Cortes J; Champlin R; O'Brien S
Cancer; 2013 Aug; 119(15):2728-36. PubMed ID: 23633004
[TBL] [Abstract][Full Text] [Related]
27. Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
Proskorovsky I; Su Y; Fahrbach K; Vandendries E; Pagé V; Onyekwere U; Wang Y; Cappelleri JC; Stelljes M
Adv Ther; 2019 Aug; 36(8):2147-2160. PubMed ID: 31140123
[TBL] [Abstract][Full Text] [Related]
28. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia.
Kantarjian H; Haddad FG; Jain N; Sasaki K; Short NJ; Loghavi S; Kanagal-Shamanna R; Jorgensen J; Khouri I; Kebriaei P; Alvarado Y; Kadia T; Paul S; Garcia-Manero G; Dabaja B; Yilmaz M; Jacob J; Garris R; O'Brien S; Ravandi F; Jabbour E
J Hematol Oncol; 2023 May; 16(1):44. PubMed ID: 37131217
[TBL] [Abstract][Full Text] [Related]
29. Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.
Kebriaei P; Wilhelm K; Ravandi F; Brandt M; de Lima M; Ciurea S; Worth L; O'Brien S; Thomas D; Champlin RE; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):296-301. PubMed ID: 23313065
[TBL] [Abstract][Full Text] [Related]
30. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
Kantarjian HM; Stock W; Cassaday RD; DeAngelo DJ; Jabbour E; O'Brien SM; Stelljes M; Wang T; Paccagnella ML; Nguyen K; Sleight B; Vandendries E; Neuhof A; Laird AD; Advani AS
Clin Cancer Res; 2021 May; 27(10):2742-2754. PubMed ID: 33602684
[TBL] [Abstract][Full Text] [Related]
31. Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.
Cassaday RD; Marks DI; DeAngelo DJ; Jabbour EJ; Advani AS; O'Brien S; Wang T; Neuhof A; Vandendries E; Kantarjian HM; Stock W; Stelljes M
Br J Haematol; 2020 Nov; 191(3):e77-e81. PubMed ID: 32805058
[No Abstract] [Full Text] [Related]
32. The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL.
Rubinstein JD; Breese EH; Krupski MC; O'Brien MM; Dandoy CE; Mizukawa B; Khoury R; Norris RE; Davies SM; Phillips CL
Transplant Cell Ther; 2023 May; 29(5):311.e1-311.e7. PubMed ID: 36809824
[TBL] [Abstract][Full Text] [Related]
33. Successful Salvage of Very Early Relapse in Pediatric Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin and HLA-haploidentical Peripheral Blood Stem Cell Transplantation With Posttransplant Cyclophosphamide.
Abematsu T; Nishikawa T; Nakagawa S; Kodama Y; Okamoto Y; Kawano Y
J Pediatr Hematol Oncol; 2022 Mar; 44(2):62-64. PubMed ID: 33512872
[TBL] [Abstract][Full Text] [Related]
34. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.
O'Brien MM; Ji L; Shah NN; Rheingold SR; Bhojwani D; Yuan CM; Xu X; Yi JS; Harris AC; Brown PA; Borowitz MJ; Militano O; Kairalla J; Devidas M; Raetz EA; Gore L; Loh ML
J Clin Oncol; 2022 Mar; 40(9):956-967. PubMed ID: 35007127
[TBL] [Abstract][Full Text] [Related]
35. [Antibody therapy for acute lymphoblastic leukemia].
Hatta Y
Rinsho Ketsueki; 2020; 61(8):922-928. PubMed ID: 32908056
[TBL] [Abstract][Full Text] [Related]
36. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.
Rubinstein JD; O'Brien MM
Front Immunol; 2023; 14():1237738. PubMed ID: 37600823
[TBL] [Abstract][Full Text] [Related]
37. Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling.
Hibma JE; Kantarjian HM; DeAngelo DJ; Boni JP
Br J Clin Pharmacol; 2019 Mar; 85(3):590-600. PubMed ID: 30536405
[TBL] [Abstract][Full Text] [Related]
38. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
Jabbour EJ; Sasaki K; Ravandi F; Short NJ; Garcia-Manero G; Daver N; Kadia T; Konopleva M; Jain N; Cortes J; Issa GC; Jacob J; Kwari M; Thompson P; Garris R; Pemmaraju N; Yilmaz M; O'Brien SM; Kantarjian HM
Cancer; 2019 Aug; 125(15):2579-2586. PubMed ID: 30985931
[TBL] [Abstract][Full Text] [Related]
39. Mini-hyper CVD + CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric B-acute lymphoblastic leukemia.
McCall D; Jabbour E; Roth M; Nunez C; Cuglievan B
Pediatr Blood Cancer; 2023 Jan; 70(1):e29939. PubMed ID: 36031729
[TBL] [Abstract][Full Text] [Related]
40. Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series.
Brivio E; Chantrain CF; Gruber TA; Thano A; Rialland F; Contet A; Elitzur S; Dalla-Pozza L; Kállay KM; Li CK; Kato M; Markova I; Schmiegelow K; Bodmer N; Breese EH; Hoogendijk R; Pieters R; Zwaan CM
Br J Haematol; 2021 Jun; 193(6):1172-1177. PubMed ID: 33529389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
